FDA report positive on Bristol-Myers cancer drug

An FDA staff report says Bristol-Myers Squibb's cancer drug dasatinib appears to slow certain types of leukemia in patients who have not responded to other treatments, such as Novartis' Gleevec. An FDA advisory panel is scheduled to meet today to consider recommending approval of dasatinib for treatment of patients with three types of leukemia.

View Full Article in:

Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Pompano Beach, FL